Japan· JP-6222007F1023
ベダキリンフマル酸塩
A bedaquiline product containing ベダキリンフマル酸塩, registered in Japan by ヤンセンファーマ, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Bedaquiline is registered in 13 of 19 countries.
Countries holding a registration under ATC J04AK05 (bedaquiline), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 8 of them publish a price we can compare per daily dose
Bedaquiline · ATC J04AK05
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ベダキリンフマル酸塩
- Manufacturer
- ヤンセンファーマ
- Country
- Japan (JP)
- ATC code
- J04AK05
- ATC class
- Bedaquiline
- Defined daily dose
- 86 mg, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- October 2, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
325 interactions on record for bedaquiline.
Graded by severity as the source publishes them — 141 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Bedaquiline · interactions on record
325 records
- 141 severe
- 182 moderate
- 2 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J04AK05
Bedaquiline, as other registers publish it.
- DenmarkSirturoJanssen-Cilag International NV
- PolandSirturoJanssen-Cilag International N.V.
- PolandSirturoJanssen-Cilag International N.V.
- DenmarkSirturoJanssen-Cilag International NV
- NorwaySirturoJanssen-Cilag International N.V.
- FinlandSIRTUROJanssen-Cilag International NV
- United StatesSIRTUROJanssen Products, LP
- FinlandSIRTUROJanssen-Cilag International NV
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cc11ca74-d565-4aac-919d-5f5653e3469c GET /v1/drugs/cc11ca74-d565-4aac-919d-5f5653e3469c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１００ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "6222007F1023",
"category": "内用薬",
"price_yen": 21636.5,
"generic_name": "ベダキリンフマル酸塩",
"product_name_jp": null,
"therapeutic_class": "6222",
"transitional_expiry": null
}See everything about bedaquiline.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.